B+
Bull case
25%
Probability
Target price
$68.25
+54.9% vs current
SUPN
SupernusBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
55%
Probability
Target price
$61.50
+39.6% vs current
B-
Bear case
20%
Probability
Target price
$51.35
+16.5% vs current
AI sentiment snapshot
Latest data as of 2026-02-25
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+88.3
Score
AI commentary
Market consensus shows modest upside vs. current quote with median targets near $61.50 and a high near $68.25, supporting a cautiously constructive tone [#SERP-5][#SERP-7]. Public aggregator pages and recent analyst notes reflect a clustered range, implying limited but tangible upside in the near term [#SERP-1].
RankAlpha Sentiment AI - 2026-02-25
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-26eventAnalyst target revisions / re-ratingHigh impact
Analyst note flow and consensus targets (range shown in public aggregates) often trigger re-rating episodes; assume window end if no single date disclosed [#SERP-1][#SERP-6].
2026-05-26catalystNext quarterly earnings (estimated)Medium impact
Quarterly results and guidance could move the stock; no confirmed date disclosed so conservatively set at +90 days (assumption). Market consensus and quote pages imply modest upside expectations [#SERP-2][#SERP-8].
2027-02-25catalystPipeline / commercial execution milestoneHigh impact
Longer-term commercial uptake or late-stage pipeline/commercial milestones could produce sustained re-rating; conservative 12‑month horizon used due to lack of a single disclosed milestone date.
Recommendation
N/A
No formal recommendation provided.
As of 2026-02-25 • Updated nightlySource: Internal modelMethodology